Search Results - "Parent, Kate L."

Electrochemical Solid-State Phase Transformations of Silver Nanoparticles by Singh, Poonam, Parent, Kate L, Buttry, Daniel A

“…Adenosine triphosphate (ATP)-capped silver nanoparticles (ATP–Ag NPs) were synthesized by reduction of AgNO3 with borohydride in water with ATP as a capping…”
Get full text

Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia by Bartlett, Mitchell J., Flores, Andrew J., Ye, Tony, Smidt, Saskia I., Dollish, Hannah K., Stancati, Jennifer A., Farrell, Drew C., Parent, Kate L., Doyle, Kristian P., Besselsen, David G., Heien, Michael L., Cowen, Stephen L., Steece-Collier, Kathy, Sherman, Scott J., Falk, Torsten

“…Parkinson's disease (PD) is the second most common neurodegenerative disease. Pharmacotherapy with L-DOPA remains the gold-standard therapy for PD, but is…”
Get full text

The Delta-Specific Opioid Glycopeptide BBI-11008: CNS Penetration and Behavioral Analysis in a Preclinical Model of Levodopa-Induced Dyskinesia by Bartlett, Mitchell J, Mabrouk, Omar S, Szabò, Lajos, Flores, Andrew J, Parent, Kate L, Bidlack, Jean M, Heien, Michael L, Kennedy, Robert T, Polt, Robin, Sherman, Scott J, Falk, Torsten

“…In previous work we evaluated an opioid glycopeptide with mixed μ/δ-opioid receptor agonism that was a congener of leu-enkephalin, MMP-2200. The glycopeptide…”
Get full text

Highly-selective µ-opioid receptor antagonism does not block L-DOPA-induced dyskinesia in a rodent model by Bartlett, Mitchell J, So, Lisa Y, Szabò, Lajos, Skinner, David P, Parent, Kate L, Heien, Michael L, Vanderah, Todd W, Polt, Robin, Sherman, Scott J, Falk, Torsten

“…Dopamine-replacement utilizing L-DOPA is still the mainstay treatment for Parkinson's disease (PD), but often leads to development of L-DOPA-induced dyskinesia…”
Get full text

The coaction of tonic and phasic dopamine dynamics by Atcherley, Christopher W, Wood, Kevin M, Parent, Kate L, Hashemi, Parastoo, Heien, Michael L

“…Tonic neurochemical dopamine activity underlies many brain functions; however a consensus on this important concentration has not yet been reached. In this…”
Get more information

Fast-Scan Controlled-Adsorption Voltammetry for the Quantification of Absolute Concentrations and Adsorption Dynamics by Atcherley, Christopher W, Laude, Nicholas D, Parent, Kate L, Heien, Michael L

“…Fast-scan cyclic voltammetry has depended on background subtraction to quantify small changes in neurotransmitter concentration. Because of this requirement,…”
Get full text

The combination of the opioid glycopeptide MMP-2200 and a NMDA receptor antagonist reduced l-DOPA-induced dyskinesia and MMP-2200 by itself reduced dopamine receptor 2-like agonist-induced dyskinesia by Flores, Andrew J., Bartlett, Mitchell J., Root, Brandon K., Parent, Kate L., Heien, Michael L., Porreca, Frank, Polt, Robin, Sherman, Scott J., Falk, Torsten

“…Dopamine (DA)-replacement therapy utilizing l-DOPA is the gold standard symptomatic treatment for Parkinson's disease (PD). A critical complication of this…”
Get full text

Platform to Enable Combined Measurement of Dopamine and Neural Activity by Parent, Kate L, Hill, Daniel F, Crown, Lindsey M, Wiegand, Jean-Paul, Gies, Kathleen F, Miller, Michael A, Atcherley, Christopher W, Heien, Michael L, Cowen, Stephen L

“…Complex behaviors depend on the coordination of the activities of ensembles of neurons and the release of neuromodulators such as dopamine. The mechanisms…”
Get full text

Differential release of dopamine in the nucleus accumbens evoked by low-versus high-frequency medial prefrontal cortex stimulation by Hill, Daniel F., Parent, Kate L., Atcherley, Christopher W., Cowen, Stephen L., Heien, Michael L.

“…The medial prefrontal cortex (mPFC) coordinates goal-directed behaviors, which may be mediated through mPFC regulation of dopamine release in the nucleus…”
Get full text

Long-term effect of sub-anesthetic ketamine in reducing l-DOPA-induced dyskinesias in a preclinical model by Bartlett, Mitchell J., Joseph, Ria M., LePoidevin, Lindsey M., Parent, Kate L., Laude, Nicholas D., Lazarus, Levi B., Heien, Michael L., Estevez, Miguel, Sherman, Scott J., Falk, Torsten

“…•Low-dose sub-anesthetic ketamine is tested in a rat l-DOPA-induced dyskinesia model.•Ketamine did not reduce abnormal involuntary movements (AIMs) after acute…”
Get full text

Fast voltammetry of metals at carbon-fiber microelectrodes: copper adsorption onto activated carbon aids rapid electrochemical analysis by Pathirathna, Pavithra, Samaranayake, Srimal, Atcherley, Christopher W, Parent, Kate L, Heien, Michael L, McElmurry, Shawn P, Hashemi, Parastoo

“…Rapid, in situ trace metal analysis is essential for understanding many biological and environmental processes. For example, trace metals are thought to act as…”
Get more information

Differential effects of the NMDA receptor antagonist MK-801 on dopamine receptor D1- and D2-induced abnormal involuntary movements in a preclinical model by Flores, Andrew J., Bartlett, Mitchell J., So, Lisa Y., Laude, Nicholas D., Parent, Kate L., Heien, Michael L., Sherman, Scott J., Falk, Torsten

“…•MK-801 worsens D1R-induced abnormal involuntary movements (limb/axial/orolingual).•MK-801 does not affect D1R-induced abnormal involuntary locomotor…”
Get full text